Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INP105 in healthy volunteers
NCT03624322Phase 1Completed
- Sponsor
- Impel Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INP105 in agitation, schizophrenia and bipolar I disorder (2 arms), sponsored by Impel Pharmaceuticals. Primary endpoints: Safety and tolerability at 30 days, PK profile of OLZ INP105 Tmax at 72 hours and 4 more. Started Aug 2018; status: completed.
02
Drugs
INP105
03
Conditions
agitationschizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT03624322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624322.